Eli Lilly's Foundayo Demonstrates Superior Efficacy Over Oral Semaglutide in Diabetes Treatment

Eli Lilly and Company announced new analysis results showing Foundayo (orforglipron) 17.2 mg led to significantly greater weight loss and improved A1C reduction compared to oral semaglutide 25 mg. These findings, relevant for adults with type 2 diabetes, are derived from an indirect treatment comparison utilizing data from the ACHIEVE-3 and PIONEER PLUS studies. This suggests a potentially more effective oral treatment option.